Şeyhmus Yiğit, Emin Ozkul
Experimental Biomedical Research - 2025;8(4):301-307
Aim: Chemerin is a novel adipokine that is being investigated as a diagnostic tool or therapeutic target in many diseases. In this prospective cross -sectional study, we aim to investigate the potential utility of serum chemerin levels as an adjunctive diagnostic tool for osteoid osteoma. Methods: This study consists of 20 patients diagnosed with osteoid osteoma (Group 1) and 20 healthy patients (Group 2). Age, gender, tumor localization, surgery types and chemerin values of all patients were recorded and evaluated. Results: A total of 40 p atients, 20 from group 1 and 20 from group 2, were included in our study. Group 1 had a median age of 17.5 (IQR: 15.25 -19.75) years, and Group 2 had a median age of 19 (IQR: 17.25 -20) years (p=0.172). In terms of gender, 60% (n=12) of Group 1 and 55% (n=11 ) of Group 2 were male ( p=0.749). Tumor nidus size varied among the participants with a median measurement of 8 (IQR: 5.25 to 8.75) mm. The median chemerin level in Group 1 was 0.94 (IQR: 0.68 -1.29), while in Group 2, it was 1.89 (IQR: 1.08 -3.72). The diff erence was statistically significant ( p<0.001). The cut -off value was determined to be 1.5, with a sensitivity of 100% and a specificity of 62% . Conclusions: The results of our research indicate that patients with osteoid osteoma have lower levels of cheme rin than healthy individuals. This suggests that chemerin may have potential as a biomarker for diagnosis. Additionally, our analysis using ROC showed that chemerin has good diagnostic capabilities.
